(20S)-Protopanaxatriol
Product Sizes
5 mg
£ POA
HY-N0835-5MG
50 mg
£ POA
HY-N0835-50MG
10 mg
£ POA
HY-N0835-10MG
100 mg
£ POA
HY-N0835-100MG
10mM/1mL
£ POA
HY-N0835-10MM
25 mg
£ POA
HY-N0835-25MG
About this Product
- SKU:
- HY-N0835
- Additional Names:
- 20(S)-APPT; g-PPT
- CAS Number:
- 34080-08-5
- Extra Details:
- (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER); and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects[1][2][3].
- Molecular Weight:
- 476.73
- Purity:
- 99.93
- References:
- [1]Leung KW, et al. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells. Br J Pharmacol. 2009 Feb;156(4):626-37.|[2]Oh GS, et al. 20(S)-protopanaxatriol inhibits liver X receptor α-mediated expression of lipogenic genes in hepatocytes. J Pharmacol Sci. 2015 Jun;128(2):71-7.|[3]Huang Q, et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):129. Published 2019 Mar 15.|[4]Zhang H, et al. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway. Int J Mol Sci. 2018;19(4):1053. Published 2018 Apr 2.
- Research Area:
- Endocrinology; Cardiovascular Disease; Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Apoptosis;Immunology/Inflammation;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
